<sup>18</sup>F-FDG PET showed reduction of glucose uptake in cortical structures, whereas <sup>18</sup>F-MPPF PET revealed an enhancement of tracer binding potential (BP<sub>ND</sub>) in key areas rich in 5-HT<sub>1A</sub> receptor involved in epilepsy, including septum, hippocampus and entorhinal cortex of kindled animals compared to controls.
These findings require further confirmation in other preclinical models and patients with epilepsy and psychiatric disorders to address the value of [<sup>18</sup> F]FDG uptake as an imaging biomarker candidate for psychiatric comorbidities in patients as well as for severity assessment in rodent epilepsy models.
Our results suggest that the quantitative analysis of <sup>18</sup>F-FDG PET/CT data is critical for patients with extratemporal epilepsies, and especially those with subtle MRI findings.